Business Monitor International


Zimbabwe Pharmaceuticals & Healthcare Report

Published 10 June 2014

  • 86 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Zimbabwe Pharmaceuticals & Healthcare Report

BMI View: Zimbabwe ' s p harmaceutical industry suffers significantly from the country ' s frail economy and ongoing political instability, with neither expected to make any meaningful recovery in the medium term. Zimbabwe continues to have one of the highest Country and Industry R isks scores in the region , and the lack of foreign investment affect s its ability to import significant amounts of active pharmaceutical ingredients, which are n ecessary for the development of the local industry. With this in mind, the lack of competition within the pharmaceutical sector could provide opportunities for foreign drugmakers that are prepared to accept high risks.

Headline Expenditure Projections

  • Pharmaceuticals: USD233mn in 2013 to USD251mn in 2014; +7.5% in US dollar terms. Forecast remains in line with last quarter's projections.

Risk/Reward Rating

In BMI's RRR table for Q3 2014, Zimbabwe scores 29 out of 100, unchanged from last quarter. The country is still ranked 28th out of the 30 markets surveyed in the Middle East and Africa (MEA) region.

Key Trends And Developments

May 2014

The Zimbabwean government is working on a comprehensive funding model which aims to improve access to quality healthcare, reports The Herald. The model will see both the employed and unemployed population pay a fixed amount towards a pool. The system hopes to ensure that individuals no longer have to pay when visiting healthcare institutions. This comes as the government moves to fulfil the Abuja Declaration, which stipulates that at least five percent of the total national budget be allocated to the health sector.

April 2014

Harare Polytechnic, a tertiary educational institution in Harare, Zimbabwe, has discovered a key ingredient used in the production of the drug Nevirapine, reports The Herald. The drug is used to prevent mother-to-child HIV transmission, and is also used as a combination drug for HIV prevention. The active ingredient for Nevirapine is imported into...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Zimbabwe 2010-2018)
16
Healthcare Market Forecast
16
Prescription Drug Market Forecast
17
Patented Drug Market Forecast
17
Generic Drug Market Forecast
18
Pharmaceutical Trade Forecast
19
Table: Pharmaceutical Trade Data And Forecasts, USDmn (Zimbabwe 2012-2018)
20
Table: Pharmaceutical Trade Data And Forecasts, ZWDmn (Zimbabwe 2012-2018)
21
Other Healthcare Data
21
Key Risks To BMI's Forecast Scenario
22
Macroeconomic Forecasts
24
Table: Zimbabwe - Economic Activity
27
Industry Risk Reward Ratings
28
Middle East & Africa Risk/Reward Ratings
28
Zimbabwe Risk/Reward Ratings
36
Rewards
36
Risks
36
Market Overview
38
Industry Trends And Developments
39
Epidemiology
39
Healthcare Sector
43
Table: Zimbabwe: Healthcare Facilities
44
Healthcare Funding
45
Health Insurance
47
Healthcare Staff
48
Traditional Medicine
49
Biotechnology
49
Clinical Trials
51
Regulatory Development
52
Regulatory Regime
52
Intellectual Property Developments
54
Counterfeit Drugs
55
Pricing And Reimbursement Regimes
55
Public Drug Procurement
56
Competitive Landscape
58
Pharmaceutical Industry
58
Domestic Industry
59
Foreign Industry
60
Pharmaceutical Sector Developments
60
Retail Pharmacy Sector
62
Company Profile
63
Datlabs
63
Varichem Laboratories
65
Ranbaxy
69
Pfizer
71
Demographic Forecast
74
Table: Zimbabwe's Population By Age Group, 1990-2020 ('000)
75
Table: Zimbabwe's Population By Age Group, 1990-2020 (% of total)
76
Table: Zimbabwe's Key Population Ratios, 1990-2020
77
Table: Zimbabwe's Rural And Urban Population, 1990-2020
77
Glossary
78
Methodology
80
Pharmaceutical Expenditure Forecast Model
80
Healthcare Expenditure Forecast Model
80
Notes On Methodology
81
Risk/Reward Ratings Methodology
82
Ratings Overview
83
Table: Pharmaceutical Risk/Reward Ratings Indicators
83
Indicator Weightings
84

The Zimbabwe Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Zimbabwe Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Zimbabwean pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Zimbabwe to test other views - a key input for successful budgeting and strategic business planning in the Zimbabwean pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Zimbabwean pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Zimbabwe.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc